COVID-19 Patients Recover Faster with Metabolic Activator Treatment, Study Shows

Their human phase 3 clinical study showed that patients with mild-to-moderate COVID-19 - who were also receiving standard care - experienced a 3.5 day reduction in recovery time when receiving the combination of metabolic activators, nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate. All four activators are aimed at improving mitochondrial function. The results of the study build on findings from phase 2 clinical data.

Through a randomized, placebo controlled, double blind phase three clinical trial, 309 outpatients were randomly assigned on a 3:1 basis to receive the metabolic activators or placebo. Patients received the combined activators or placebo twice a day for 14 days and clinical status was evaluated through daily telephone check-ins.

“Our phase 3 data shows that metabolic activators significantly improve the recovery, liver health, and markers of inflammation of patients with COVID-19,” said the study’s lead author, Adil Mardinoglu, professor at KTH and Kings College and research fellow at SciLifeLab. “Dysfunctional mitochondria have been implicated in worsened progression for COVID-19, and we are pleased to find that the combination of these metabolic activators helps to remedy the stress put on the body of an infected patient.”

Related Links:
KTH Royal Institute of Technology